Stakeholder Forum 2010

Start Date 14/06/2010 End Date 15/06/2010

The Innovative Medicines Initiative welcomed 270 high level industry representatives, regulators, policy makers, top level scientific experts, patient representatives and science leaders at its first Stakeholder Forum in Brussels.

The event featured interesting presentations and lively discussions about the ongoing IMI projects, the IMI research agenda, the 3rd Call (2010) research topics and the IMI intellectual property policy.



Plenary Sessions - 14 June 2010

Welcome and introduction (386kb)
Michel Goldman, Executive Director IMI

Reshaping biopharmaceutical research in Europe (109kb)
Roch Doliveux, Chief Executive Officer UCB

Public-Private Partnerships in the Health sector: the EU perspective (361kb)
Philippe Cupers, DG Research, European Commission

How to accelerate approval of innovative drugs (791kb)
Bruno Flamion, European Medicines Agency EMA

Patients' expectations (1.5MB)
Nicola Bedlington, Director European Patients' Forum

Opportunities for research organisations (155kb)
Stavros Malas, Chair States Representatives Group

Achievements and challenges ahead (244kb)
Michel Goldman, Executive Director IMI


Plenary sessions - 15 June 2010

Lessons learnt (61kb)
Michel Goldman, Executive Director IMI

The 3rd Call for proposals (2010) (266kb)
Titta Rosvall-Puplett, Director Research Directors Group, EFPIA
(Updated version - 29 June 2010)

New ways of sharing knowledge (113kb)
Magali Poinot, Legal Manager IMI

Revision of the IMI scientific strategy: Towards a new Research Agenda (700kb)
Christian Noë, chair of the Scientific Committee


Workshops on ongoing IMI Projects - 15 June 2010


  • eTOX (493kb)
    Ferran Sanz, Fundació IMIM
  • SAFE-T (4MB)
    Michael Merz, Novartis
  • PROTECT (534kb)
    Xavier Kurz, European Medicines Agency
  • MARCAR (428kb)
    Jonathan Moggs, Novartis


  • PHARMA-COG (937kb)
    Alexandra Auffret, University of Marseille
  • NEWMEDS (353kb)
    Tine Bryan Stensbøl, H. Lundbeck
  • EUROPAIN (164kb)
    Märta Segerdahl, AstraZeneca


  • Eu2P (2.1MB)
    Deborah Szafir , F. Hoffmann- La Roche
  • EMTRAIN (1.9MB)
    Mike Hardman, AstraZeneca
  • SAFESCIMET (300kb)
    Theodor Guentert, F. Hoffmann - La Roche
  • PHARMATRAIN (211kb)
    Fritz Buhler, University of Basel


  • U-BIOPRED (1.2MB)
    Chris Compton, Novartis
    Thierry Troosters, Katholieke Universiteit Leuven
  • IMIDIA (2.7MB)
    Bernard Thorens, Université de Lausanne & Alain Ktorza, Institut de Recherches Servier
  • SUMMIT (1.4MB)
    Leif Groop, Lund University & Michael Mark, Boehringer Ingelheim